Acebilustat for Coronavirus (COPPS Trial)

"There are presently 2 ongoing studies involving Acebilustat. Of these, 0 are in the final Phase 3 stage. Most of the research is based at Stanford University; however, there are also 3 other clinical trial sites."

"Unfortunately, this particular clinical trial is no longer admitting patients. The study was originally posted on April 23rd, 2021 but was last updated on September 12th, 2022. There are currently 1137 other trials involving covid-19 that are still enrolling patients as well as 2 other trials for Acebilustat."

"Because there is only data supporting safety and no efficacy for Acebilustat, it received a score of 2."

"Eligibility for this clinical study requires that potential patients are aged 18 to 80. However, there are 145 other trials available for minors and 988 different studies open to people over the age of 65."

"This study is seeking 120 individuals that have contracted covid-19 and are between 18-80 years old. There are certain additional requirements that must be met in order to qualify which are as follows: At the start of the trial, applicants must have at least two symptoms with a mild or higher severity score OR one symptom with a moderate severity score., The individual's first symptom related to COVID-19 should have occurred within the week prior to being randomized for the study., Must be an outpatient, Other inclusion criteria specific to the investigational product that may, in the eyes of the investigator, be deemed necessary.."

"Unfortunately, this particular trial is not currently seeking participants. Although, it was first posted on April 23rd 2021 and edited most recently on September 12th 2022. For those looking for other studies, there are 1137 trials actively recruiting patients with covid-19 and 2 studies for Acebilustat that still need participants."